[Gn글로벌]

Pipeline

Outline

<div class="pop_tit"><strong>PnP-001 (Burns treatment)</strong></div>

<div class="pop_content pop01">
		<div class="con_g con01">
			<div class="con_tit">
				<strong>Current status of commercialization of wound treatment</strong>
			</div>
			
			<div class="pop01_con">
				<div class="img_g">
					<div class="txt_box">
						<div class="tit"><em>Indications. Entry markets</em><p><strong></strong>Commercialization in progress</p></div>
					</div>
					<div class="img_wrap">
						<img src="/e_images/sub/pop01_img01.png" alt="" />
					</div>
				</div>
				<div class="ul_box">
					<div class="tit"><em>Commercialization strength</em></div>
					<ul>
					<li>
						<strong>Wound treatment market CAGR 7%▲</strong>
						<span>9.95 billion USD in 2011 ▶ <br /> 18.5 billion USD in 2021</span>
						</li>
						<li>
						<strong>Growth factor market CAGR 24%▲</strong>
						<span>(1.2 billion USD as of 2014)</span>
						</li>
						<li>
							<strong>Wound treatment market expected to maintain solid growth due to global aging</strong>
						</li>
						<li>
							<span>Can be developed in various forms such as medical devices and biobetter drugs</span>
						</li>
						<li>
							<strong>Pre-clinical stage in progress  ▶</strong>
							<strong>Clinical stage entry in 2022</strong>
						</li>
				</ul>
				</div>
				
			</div>
		</div>
		<div class="con_g con02">
			<div class="con_tit">
				<strong>Superiority of PnP-001 compared with existing burn treatment</strong>
			</div>
			<div class="pop01_con">
				<table>
					<colgroup>
						<col width="25%">
						<col width="37.5%">
						<col width="37.5%">
					</colgroup>
					<thead>
						<tr>
							<th></th>
							<th>PnP-001 <br />(Stable bFGF)</th>
							<th>Fiblast <br />(Wild-type bFGF)</th>
						</tr>
					</thead>
					<tbody>
						<tr>
							<td>Manufacturer</td>
							<td>PnP Biopharm (Korea)</td>
							<td>Kaken (Japan)</td>
						</tr>
						<tr>
							<td>Temperature</td>
							<td>Conservable & deliverable at Room temp.</td>
							<td>Conservable & deliverable at 4°C</td>
						</tr>
						<tr>
							<td>Formulations</td>
							<td>Liquid types, spray types, <br />  ointments, dressings, etc.</td>
							<td>Powder type</td>
						</tr>
						<tr>
							<td>Expiration</td>
							<td>Over 1 year in solution</td>
							<td>2 weeks in solution</td>
						</tr>
						<tr>
							<td>Applications</td>
							<td>Very broad due  <br />to high stability</td>
							<td>Very limited due to <br /> low stability</td>
						</tr>
					</tbody>
				</table>
				<p class="ref">* Wound Management, Worldwide Market and forecast to 2021</p>
			</div>
		</div>
	</div>

<div class="pop_tit"><strong>PNP-001(상처드레싱제)</strong></div>

<div class="pop_content">
		<div class="con_g con01">
			<div class="con_tit">
				<strong>대사질환 치료제 개발</strong>
			</div>
			<div class="con_g_inner">
				<div class="pop02_con01">
					<div class="txt_box">
						<div class="tit"><em>치료제 소개 </em></div>
					</div>
					<ul class="clfix">
						<li>높은 안정성</li>
						<li>면역항원성 전무</li>
						<li>PNP-002 <br />(아디포넥틴 아날로그)</li>
						<li>다양한 대사성 <br />질환 적용 가능</li>
						<li>경구용 등 다양한 <br />형태로 제작 가능</li>
					</ul>
				</div>
				<div class="pop02_con02">
					<div class="txt_box">
						<div class="tit"><em>사업진행 및 적응증</em></div>
					</div>
					<div class="img_wrap">
						<img src="/e_images/sub/pop02_img02.jpg" alt="" />
					</div>
				</div>
			</div>
		</div>
		<div class="con_g con01_mob">
			<img src="/e_images/sub/sub02_PNP002_mob.png" alt="">
		</div> 	
		<div class="con_g con02">
			
			<div class="con_tit">
				<strong>기존 치료제 대비 차별성</strong>
			</div>
			<div class="pop02_con03">
				<ul>
					<li>비만이 주요 원인으로 발생하는 <br />대사성 질환 환자 증가</li>
					<li>골다공증 시장 <br />2018년 115억USD (CAGR 0.3%)</li>
					<li>연골재생 (CAGR 12.5%▲) <br />2020년 8억USD ▶ 2025년 16억USD</li>
					<li>비만 (CAGR 26.4%▲) <br />2015년 39억USD ▶ 2024년 156억USD </li>
				</ul>
			</div>
		</div>
	</div>

<div class="pop_tit"><strong>PnP-101 (Prostate cancer theranostics)</strong></div>
	<div class="pop_content">
		<div class="con_g con01">
			<div class="con_tit" style="background: #7087aa; margin-bottom: 0;">
				<strong>BexBody™</strong>
			</div>
			<div class="pop03_con01">
				<div class="pop03_con01_1">
					<ul>
						<li>
							<div>
								<div class="img_wrap">
									<img src="/e_images/sub/pop03_icon01.png" alt="" />
								</div>
								<div class="txt_box">
									<p>Camelid animals<br />(Alpaca, Llama, etc.)</p>
								</div>
							</div>
							<ul>
								<li>A tenth size of human IgG </li>
								<li>High affinity and specificity</li>
								<li>High sequence homology<span>  → Low immunogenicty</span></li>
							</ul>
						</li>
						<li>
							<div class="img_wrap">
								<img src="/e_images/sub/pop03_icon03.png" alt="" />
							</div>
							<div class="txt_box">
								<p>B cell<br />(Antibody-producing cell of lymphocytes)</p>
							</div>
						</li>
						<li>
							<div class="img_wrap">
								<img src="/e_images/sub/pop03_icon04.png" alt="" />
							</div>
							<div class="txt_box">
								<p>BexBody™ library construction</p>
							</div>
						</li>
					</ul>
				</div>
				
				<div class="pop03_con01_2">
					<ul>
						<li><img src="/e_images/sub/pop03_icon05.png" alt="" /></li>
						<li>Antibody drug development combined<br />with BexBody™ platform technology with high affinity</li>
						<li>New antibody drug R&D</li>
					</ul>
				</div>
				<div class="pop03_con01_mob">
					<img src="/e_images/sub/sub02_pnp003_mob.png" alt="">
				</div>
				<div class="pop03_con01_3">
					<p>PnP Biopharm platform technology BexPress™</p>
					<ul>
						<li>
							<div class="txt_box">
								<img src="/e_images/sub/pop03_icon07.png" alt="" />
								<strong>High functionality protein, peptide design technology</strong>
							</div>
						</li>
						<li>
							<div class="txt_box">
								<img src="/e_images/sub/pop03_icon08.png" alt="" />
								<strong>Recombinant protein production technology</strong>
							</div>
						</li>
						<li>
							<div class="txt_box">
								<img src="/e_images/sub/pop03_icon09.png" alt="" />
								<strong>Protein stabilization technology</strong>
							</div>
						</li>

</ul>
				</div>

</div>
		</div>

<div class="con_g con02">
			<div class="con_tit">
				<strong>Prostate cancer BexBody™ therapeutics (PnP-101)</strong>
			</div>
			<div class="pop03_con03">
				<ul>
					<li>Theranostics accompanied by treatment and diagnosis Diagnosis and radiation therapy of cancer possible at the same time </li>
					<li>Global aging ▶ <br />Main cause of increased prostate cancer incidence rate<br />Prostate cancer antibody drug market CAGR 8% ▲ <br />10 billion USD in 2019 ▶ 19.6 billion USD in 2027</li>
					<li>Synthetic chemical compound + high affinity & specificity<br /> ▶ A pre-clinical stage entry of anti-PSMA BexBody in 2023</li>
				</ul>
			</div>
		</div>
	</div>

<div class="pop_tit"><strong>PnP-101 (Prostate cancer diagnostics)</strong></div>
<div class="pop_content">
		<div class="con_g con01">
			<div class="con_tit" style="background: #7087aa; margin-bottom: 0;">
				<strong>BexBody™</strong>
			</div>
			<div class="pop04_con01">
				<div class="pop04_con01_1">
					<ul>
						<li>
							<div>
								<div class="img_wrap">
									<img src="/e_images/sub/pop03_icon01.png" alt="" />
								</div>
								<div class="txt_box">
									<p>Camelid animals<br />(Alpaca, Llama, etc)</p>
								</div>
							</div>
							<ul>
								<li>A tenth size of human IgG </li>
								<li>High affinity and specificity</li>
								<li>High sequence homology<span>  → Low immunogenicty</span></li>
							</ul>
						</li>
						<li>
							<div class="img_wrap">
								<img src="/e_images/sub/pop03_icon03.png" alt="" />
							</div>
							<div class="txt_box">
								<p>B cell<br />(Antibody-producing cell of lymphocytes)</p>
							</div>
						</li>
						<li>
							<div class="img_wrap">
								<img src="/e_images/sub/pop03_icon04.png" alt="" />
							</div>
							<div class="txt_box">
								<p>BexBody™ library construction</p>
							</div>
						</li>
					</ul>
				</div>
				<div class="pop04_con01_2">
					<ul>
						<li><img src="/e_images/sub/pop03_icon05.png" alt="" /></li>
						<li>Antibody drug development combined<br />with BexBody™ platform technology with high affinity</li>
						<li>New antibody drug R&D</li>
					</ul>
				</div>
				<div class="pop04_con01_mob">
					<img src="/e_images/sub/sub02_pnp003_mob.png" alt="">
				</div>
				<div class="pop04_con01_3">
					<p>PnP Biopharm platform technology BexPress™</p>
					<ul>
						<li>
							<div class="txt_box">
								<img src="/e_images/sub/pop03_icon07.png" alt="" />
								<strong>High functionality protein, peptide design technology</strong>
							</div>
						</li>
						<li>
							<div class="txt_box">
								<img src="/e_images/sub/pop03_icon08.png" alt="" />
								<strong>Recombinant protein production technology</strong>
							</div>
						</li>
						<li>
							<div class="txt_box">
								<img src="/e_images/sub/pop03_icon09.png" alt="" />
								<strong>Protein stabilization technology</strong>
							</div>
						</li>

</ul>
				</div>
				</div>
		</div>

<div class="con_g con02">
			<div class="con_tit">
				<strong>Prostate cancer BexBody™ diagnostic kit (PnP-101)</strong>
			</div>
			<div class="pop04_con03">
				<ul>
					<li>
						Prostate cancer diagnosis based on prostate cancer-specific makers’ level Prostate cancer antibody-based diagnosis market CAGR 15.2% ▲   <br />3.2 billion USDin 2020 ▶ 9.94 billion USD in 2028
					</li>
					<li>BexBody™ <br />Cost-effective and low cost production in E. coli <br>High affinity and high resistance against acidic or high temperature conditions</li>
					<li>Development of prostate cancer diagnostic kit using urine or blood samples ▶ Clinical stage entry in 2022 / KFDA approval in 2023</li>
				</ul>
			</div>
		</div>
	</div>

<div class="pop_tit"><strong>PnP-201 (Anti-cancer combi-therapy)</strong></div>

<div class="pop_content01 pop05">
		<div class="pnp05_mob_img">
			<img src="/e_images/sub/sub02_pnp005_mob.png" alt="">
		</div>
		<div class="con_g con01">
			<div class="con_tit">
				<strong>Selection of candidates</strong>
			</div>
			<div class="img_wrap pop05_img_wrap">
				<img src="/e_images/sub/pop05_img01.jpg" alt="" class="pc"/>
				<img src="/e_images/sub/pop05_img01_tab.jpg" alt="" class="tab"/>
			</div>
		</div>
		<div class="con_g con02">
			<div class="con_tit">
				<strong>High applicability and versatility</strong>
			</div>
			
			<div class="pop05_con01">
				<div class="pop05_con01_1">
					<ul>
						<li><p>Diverse antibody therapeutics</p><span>+</span><p>Intravenous administrative drugs</p></li>
						<li><img src="/e_images/sub/pop05_icon01.png" alt="" /><p>Development of subcutaneous injectable drugs</p></li>
						<li><p>Diverse protein therapeutics</p></li>
					</ul>
				</div>
				<div class="pop05_con01_2">
					<ul>
						<li>
							<p>Existing intravenous administrative drugs mostly used by experts</p>
							<span>VS</span>
							<p>Subcutaneous injectable drugs that can be used by the general public and elderly caregivers (same type as insulin for diabetes)</p>
						</li>
						<li><strong>Development of subcutaneous injectable drugs with high applicability and versatility in progress</strong></li>
					</ul>
				</div>
			</div>

<div class="con_tit">
				<strong>High stability and long-acting property  </strong>
			</div>
		</div>
	</div>

<div class="pop_tit"><strong>PnP-001 (Wound-dressing material)</strong></div>

<div class="pop_content01 pop06">
		<div class="pnp06_mob_img">
			<img src="/e_images/sub/sub02_pnp006_mob.png" alt="">
		</div>
		<div class="con_g con01">
			<div class="con_tit">
				<strong>Development in progress</strong>
			</div>
			<div class="txt_box">
				<div class="tit"><em>Development of wound-dressing material for medical device</em></div>
			</div>
			<div class="pop06_con01">
				<div class="pop06_con_inner">
					<div class="img_g">
						<div class="img_wrap">
							<img src="/e_images/sub/pop06_img01.png" alt="" />
						</div>
						<div class="img_wrap">
							<img src="/e_images/sub/pop06_img02.png" alt="" />
						</div>
					</div>
					<div class="txt_g">
						<div class="txt_wrap">
							<p>Completed pre-clinical study of finished product, global licensing-out in preparation</p>
						</div>
						<div class="txt_wrap">
							<p>Stable-bFGF raw material</p>
							<p>Pre-clinical toxicology and efficacy test <br> in progress</p>
							<span>- Toxicity: no significant toxicity up to 500 ppm</span>
							<span>- Efficacy: effective for diabetic foot ulcer<br>  (type 1 & 2)</span>
						</div>
					</div>
				</div>
				<div class="pop06_txt"><img src="/e_images/sub/pop06_icon01.png" alt="" /><p>Clinical stage entry in preparation for KFDA approval </p></div>
			</div>
		</div>
		<div class="con_g con02">
			<div class="con_tit">
				<strong>Expected effect</strong>
			</div>
			<div class="pop06_con02">
				<p>Main indication</p>
				<ul>
					<li>
						<div class="img_wrap">
							<img src="/e_images/sub/pop06_img03.png" alt="" />
						</div>
						<strong>Diabetic foot ulcer</strong>
					</li>
					<li>
						<div class="img_wrap">
							<img src="/e_images/sub/pop06_img04.png" alt="" />
						</div>
						<strong>Bed sore</strong>
					</li>
					<li>
						<div class="img_wrap">
							<img src="/e_images/sub/pop06_img05.png" alt="" />
						</div>
						<strong>Burns</strong>
					</li>
				</ul>
			</div>
			<div class="pop06_con03">
				<p>Expected sales size</p>
				<div class="img_wrap">
					<img src="/e_images/sub/pop06_img06.png" alt="" />
				</div>
				<ul>
					<li><span>Domestic</span><p>2 billion KRW out of 30 billion KRW (raw material supply)</p></li>
					<li><span>Global</span><p>Global: 15~20 billion KRW (raw material supply + finished product sales)</p></li>
				</ul>
			</div>
		</div>
	</div>

<div class="pop_tit"><strong>PnP-001 (Dry eyes treatment)</strong></div>

<div class="pop07_content">
		<div class="con01">
			<div class="tit">
				<em>Current status of commercialization of dry eye treatment</em>
			</div>
			<div class="box">
				<div class="img_wrap">
					<img src="/e_images/sub/sub0502_pop_img01_pc.jpg" class="pc_img" style="width:100%;" alt="">
					<img src="/e_images/sub/sub0502_pop_img01_pc.jpg" class="tab_img" alt="">
					<img src="/e_images/sub/sub0502_pop_img01_pc.jpg" class="mob_img" alt="">
				</div>
				<div class="txt">
					<em>Commercialization strength</em>
					<ul>
						<li>
							<p>
								Global dry eye disease drug market CAGR 6 % <br>	
								’3.9 billion USD in 2018 ▶ 5.6 billion USD in 2026   <br>
								*domestic maket 0.3 billion USD in 2020 ▶ 0.45 billion USD in 2027
							</p>
						</li>
						<li>
							<p>
								Dry eye disease drug market expected to maintain solid growth due to global aging and accelerating industrialization
							</p>
						</li>
						<li>
							<p>
								Existing growth factors ▶  Activity not persisting in formulations such as eye drops or ointments with low stability
							</p>
						</li>
						<li>
							<p>PnP-stable growth factors ▶ Can be developed in various forms such as medical devices and biopharmaceuticals due to high stability</p>
							
						</li>
						<li>
							<p>*Efficacy test ▶ <br>Pre-clinical stage entry in 2023</p>
						</li>
					</ul>
					<b>* Selected for the 2022 SME technology innovation development project</b>
				</div>
			</div>
			<strong>Stable growth factor-based dry eye treatment with dual effects of anti-inflammation and corneal regeneration</strong>
		</div>
		<div class="con02">
			<div class="tit">
				<em>Differentiation from existing dry eye treatments</em>
			</div>
			<div class="box01">
				<p>
					Double blocking of the inflammatory circuit, the main pathological mechanism of dry eye disease, by inhibiting the inflammatory response and regenerating the corneal epithelial defect through growth factors ▶ Fundamental recovery of the homeostasis of the ocular surface
				</p>
			</div>
			<div class="box02">
				<img src="/e_images/sub/sub0502_pop_img02_pc.jpg" class="pc_img" style="width:100%;" alt="">
				<img src="/e_images/sub/sub0502_pop_img02_pc.jpg" class="tab_img" style="width:100%;" alt="">
				<img src="/e_images/sub/sub0502_pop_img02_mob.jpg" class="mob_img" style="width:333px;" alt="">
				<p>The dry eye treatment market is led by two anti-inflammatory drugs: Restasis from Allergan in the US and Zydra from Shire. Restasis relieves inflammation, but has a side effect of complaining of stinging eyes, and Zydra has a good corneal epithelial protective effect, but the inflammatory treatment effect is relatively low.</p>
				<p>Most of the existing treatments are targeted for anti-inflammatory treatment. A stabilized growth factor-based dry eye treatment that exhibits dual effects of anti-inflammation and corneal regeneration, which we intend to develop, is differentiated from other products and can dominate the market.</p>
			</div>
		</div>
	</div>

Company Profile

Core Technology

Pipeline

Product

PR